Friday, July 8, 2016

New trial recruiting!!! Pembro plus MGA271 for folks (melanoma, urothelial cancer and more) who progressed on systemic therapy including immuno!!!

Y'all know I am apt to get excited about small things...but....this seems to hold real promise for folks who have progressed on a variety of treatments.  This study combines MGA271 with pembro for a variety of folks with solid tumors.  So what is this MGA271?  At the moment it is called Enoblituzumab, a B7-H3 monoclonal antibody.  Here's a link to a presentation that explains, followed by selected slides:

Interim results of an ongoing Phase 1, Dose escalation study of MGA271 (Enoblituzumab) an Fc-optimized humanized Anti-B7-H3 monoclonal antibody, in patients with advanced solid cancer

What is super cool about all of  See the second line on the slide above?  These folks are POST ipi, anti-PD1 or some various combo of the two!!!

Here is a link to a report of the new trial for Enoblituzumab combined with Pembro:  A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing cancer

Here's a link to the study at  Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer

The trial seems to be actively recruiting in Baltimore, New York, Philadelphia, and San Antonio.  Now this is a Phase 1 study...making the ratties - ratties for realz!!! But....everybody gets the drug.  Just thinking this may be a real option for folks for whom neither ipi nor the anti-PD1 products worked.  (We'll keep looking at how it does, Joshie!!!!)

Good thing ratties have long tails!!!  love, c


  1. News like this gives me a real lift. Hopefully we can all lick this cancer thing soon. Yes, thanks so much Les.

  2. So happy to see other options for those of us who've progressed on current standard treatments. You da best Bubbles!!!